Navigation Links
NPS Pharmaceuticals Commences Tender Offer for 3.0% Convertible Notes Due 2008

PARSIPPANY, N.J., Sept. 6 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it has commenced a cash tender offer for any and all of its outstanding 3.0% Convertible Notes due 2008. The tender offer will expire at midnight, Eastern Time on October 4, 2007, unless extended. The tender offer, which is described fully in an offer to purchase and the related letter of transmittal, is not subject to the receipt of any minimum amount of tenders.

NPS Pharmaceuticals is purchasing the notes to reduce outstanding debt and reduce interest expense. The tender offer will be funded from the proceeds of the company's recently completed offering of $50 million aggregate principal amount of 5.75% convertible notes due August 7, 2014, a private placement of $100 million of secured 15.5% Sensipar B Bonds due March 30, 2017 completed by its subsidiary and a $50 million up-front payment received from Drug Royalty L.P.3 as part of the NPS Pharmaceuticals' sale and assignment of its right to receive royalty payments on sales of PREOTACT(R). NPS Pharmaceuticals is offering to purchase the notes at a price of $982.50 for each $1,000 of principal amount of notes tendered, plus accrued and unpaid interest up to, but not including, the date the notes are paid pursuant to the offer.

NPS Pharmaceuticals has retained Jefferies & Company, Inc. to act as Dealer Manager in connection with the offer.

U.S. Bank National Association has been appointed to act as the depositary for the offer, and D.F. King & Co., Inc. has been appointed to serve as information agent. Questions and requests for assistance and copies of the offer to purchase and the related letter of transmittal may be directed to the information agent at (212) 269-5550, for banks and brokers, or (888) 644-5854 for others.

Neither the NPS Pharmaceuticals Board of Directors nor any other person makes any recommendation as to whether holders of notes should tender their notes, and no one has been authorized to make such a recommendation. Holders of notes must make their own decisions as to whether to tender their notes, and, if they decide to do so, the principal amount of notes to tender.

This announcement is not an offer to buy or the solicitation of an offer to sell any notes. The tender offer for NPS Pharmaceuticals' 3.0% Convertible Notes due 2008 will be made solely by and subject to the terms and conditions set forth in a Schedule TO (including an offer to purchase, related letter of transmittal and other tender offer documents) that is being filed by NPS Pharmaceuticals today with the Securities and Exchange Commission. The Schedule TO will contain important information and should be read carefully before any decision is made with respect to the tender offer. The offer to purchase, letter of transmittal and other tender offer documents are being delivered to holders of the notes. Once the Schedule TO and other documents are filed with the SEC, they will be available free of charge on the SEC's website at, on NPS Pharmaceuticals' website at or by contacting the NPS Pharmaceuticals Corporate Secretary at (800) 730-3644.

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website,

This press release contains forward-looking statements intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements relating to strategies, expectations, intentions, plans, future events, performance, underlying assumptions, and other statements that do not relate strictly to historical or current facts. Although NPS Pharmaceuticals' management believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. These statements can be affected by inaccurate assumptions and by a variety of risks and uncertainties, including, among others, general economic conditions, the success of the tender offer for the 3.0% Convertible Notes due 2008 and the amount of any such notes actually tendered for repurchase or actually repurchased by the company, the company's reported results meeting the company's guidance and the expectations of the market, and other risks, including risks related to NPS Pharmaceuticals' operations and financial condition, detailed in NPS Pharmaceuticals' Annual Report on Form 10-K for the year ended December 31, 2006, NPS Pharmaceuticals' Quarterly Reports on Form 10-Q for the quarters ended March 31, 2007 and June 30, 2007 and any other reports of the company filed with the Securities and Exchange Commission. Should one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expressed or implied in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of this date. NPS Pharmaceuticals does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a discussion of these risks, uncertainties and assumptions, investors are urged to refer to NPS Pharmaceuticals' reports filed with the Securities and Exchange Commission.

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Midwest colleges strong contenders for NIH funds
4. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
5. Ambion Offers Gene Expression Profiling Service
6. CIO Leadership Series: Snap-Ons Moreno offers lessons in IT transformation
7. In pursuit of capital, be sure to track your private offering
8. Ethics Board site offers welcome contrast to state IT mistakes
9. Visions: Preizler offers insurers perspective on healthcare IT
10. State to offer $850K in high-tech training grants
11. Hewlett-Packard exec offers innovative counsel
Post Your Comments:
(Date:10/8/2015)... -- Celemics, a global pioneer of personalized medicine genetics, ... with the establishment of Celemics America, Inc. ... , has secured itself in the global market ... preparation for DNA sequencing and genetic testing.  Next Generation ... testing more accurately, quickly, and cost effectively than traditional ...
(Date:10/8/2015)... 2015 The 2015 Nobel Prize in Chemistry ... at Dallas. Aziz Sancar , who earned his PhD ... in 1977, is one of three scientists who received the ... repair damaged DNA on a molecular level.  --> Aziz ... from UT Dallas in 1977, is one ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... 2015 , ... Talon Innovations, a provider of Precision Machined Products ... it is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in ... Talon Innovations was recognized as a nominee for this competitive award. , The ...
Breaking Biology Technology:
... DUBLIN , June 17, 2010 An ... hour blood,pressure is more accurate and consistent than a leading group of,international ... ... the study,analysed the interpretation of numerous blood pressure readings taken over a,24-hour ...
... becoming increasingly flatter - some have even become almost as ... dimensions, much to the delight of home cinema fans. Cellphones ... All of these developments owe their thanks to miniature light-emitting ... multitude of devices. However, LED technology does have a ...
... ... an occlusion-induced IR injury model enabling the ability to study the functional relevance of ... which the drug promotes myocardial protection. , ... (PRWEB) June 16, 2010 -- MD Biosciences , a ...
Cached Biology Technology:
(Date:9/28/2015)... September 28, 2015 According to ... & Software), Product (Scanner & Others), Application (Access Control ... & Others) & Geography Global - Forecast to 2020", published ... reach USD 3627.90 Million by 2020, at a CAGR ... Browse 65 market data T ables and ...
(Date:9/26/2015)...  Results of a TactioRPM pilot project in ... the Stanford Medicine X Conference. In a presentation ... Health Devices and Pharmacogenomics", Roger Simard , ... how senior patients equipped with connected health devices ... the TactioRPM remote patient monitoring platform were empowered ...
(Date:9/24/2015)... , September 24, 2015 ... september 2015 Kerv ( ... finanstjänster, lanserar idag världens första kontaktlösa betalningsring ... in 77 000 GBP för massproduktion via ... ) , Kerv-bärare kan ...
Breaking Biology News(10 mins):
... part in the National Science Foundation,s (NSF) Faculty ... additional distinction as winners of Presidential Early Career ... 2006 competition. The PECASE program recognizes outstanding ... show exceptional potential for leadership at the frontiers ...
... wildfires can contribute as much as vehicles to carbon ... highly variable. New research published in the online open ... and suggests fires will complicate emissions monitoring and modelling ... Atmospheric Research and Jason Neff of the University of ...
... State University have designed a revolutionary laser technique which ... damaging human cells and may also help reduce the ... The research, published on Thursday November 1 in ... discusses how pulses from an infrared laser can be ...
Cached Biology News: